ATS (ATS) Raymond James 46th Annual Institutional Investors Conference summary

Business overview and market focus

• Operates in regulated markets including life sciences, food safety, nuclear energy, consumer products, and automotive, with life sciences as the largest segment.

• Provides end-to-end automation solutions, from production lines to ongoing service and support.

• Focused on resilient end markets, with about 80% of business in regulated spaces.

• Custom automation, standard machines, services, and digital solutions are core offerings.

Life sciences growth and innovation

• Achieved the second largest bookings quarter in company history, with a 1.18 trailing 12-month book-to-bill ratio.

• GLP-1 drugs represent about 10% of business and are expected to have a strong future tail.

• Symphoni technology enables double output and half the footprint for GLP-1 drug production.

• Growth also seen in radiopharmaceuticals, wearables, and pharmacy automation.

• Automation enables customers to improve margins and reshore production, as seen with Insulet's Omnipod.

M&A strategy and execution

• Completed 26 acquisitions in the past five to six years, focusing on cultivated deals.

• Recent Heidolph acquisition expected to be profitable in year one and accretive by year two or three.

• Integration playbook emphasizes financial controls, supply chain leverage, and commercial execution.

• Maintains a disciplined approach with strict ROIC criteria for targets.